Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Tau Positron Emission Tomography (PET) in Imaging and Cognition

Authors not listed

Yaakov Stern · 2018

Abstract

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-07-02 MST

Cite this

APA
Anonymous. (2018). Tau Positron Emission Tomography (PET) in Imaging and Cognition. <em>Yaakov Stern</em>. https://clinicaltrials.gov/study/NCT03372317
Vancouver
Anonymous. Tau Positron Emission Tomography (PET) in Imaging and Cognition. Yaakov Stern. 2018.
BibTeX
@misc{anon2018TauPos, title = {Tau Positron Emission Tomography (PET) in Imaging and Cognition}, author = {Anonymous}, journal = {Yaakov Stern}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings